Navigation Links
Asthma Sufferers Favor Quick Relief Over Long-term Control

People who currently have asthma are much more likely to rely on drugs that offer quick relief for symptoms such as shortness of breath, wheezing, or coughing, // than medications for long-term control, according to the latest News and Numbers issued by the Agency for Healthcare Research and Quality.

Approximately 31 percent of sufferers say that they use quick-relief medications to control symptoms of asthma, compared with about 14 percent who rely on longer-term preventive medicines for control. Another 31 percent use both types of medications and 24 percent use none.

The federal study further found that among people whose asthma was active when surveyed:

? More than one-fourth reported having a peak flow meter at home for measuring their ability to expel air from their lungs.

? Nearly half (48 percent) of adults said they had at least one asthma attack within the previous 12 months.

? Women were more likely to have asthma attacks than men – 50 percent versus 40 percent

AHRQ, a part of the U.S. Department of Health and Human Services, works to improve the quality, safety, efficiency and effectiveness of health care in the United States. The data in this AHRQ News and Numbers comes from the Agency’s Medical Expenditure Panel Survey, a highly detailed source of information on the health services that Americans use, how frequently they use them, the cost of these services, and how they are paid.

Source-Newswise
SR
'"/>




Page: 1

Related medicine news :

1. New Drug for Bronchial Asthma
2. Asthma may actually be prevented by Dust and Dirt
3. Inhaled Steroids Safe & Effective for Children with Asthma
4. What happens when Asthmatics consume Aspirin?
5. Asthma! A new warning for heart disease
6. Asthma linked to obesity
7. Higher Risk of Asthma in children with autoimmune disease
8. Asthmatics at increased risk of lung cancer
9. Cleanliness might lead to Asthma
10. Asthma is not just a childhood condition
11. Asthma not just a childhood condition
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... San Francisco, California (PRWEB) , ... December 08, 2016 , ... ... health coaches, has raised an $18M Series B led by Canvas Ventures . ... use the capital to scale its mobile platform to serve more consumers who are ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Dan Carlisle Agency, ... Jefferson County, is announcing the launch of a charity drive to raise support ... homeless women and children in Birmingham has grown steadily since the 1980’s, and ...
(Date:12/8/2016)... , ... December 08, 2016 , ... The Compretta Insurance ... and residential clients in and around the Hancock County area, is announcing the launch ... County Food Pantry. , The Hancock County Food Pantry has worked for more than ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... DrugDev ... the announcement that it is one of the early adopters completing EU-U.S. Privacy Shield ... is designed to provide companies on both sides of the Atlantic with a mechanism ...
(Date:12/7/2016)... Kenosha, Wisconsin (PRWEB) , ... December 07, 2016 , ... ... the extraordinary new MedMaster™ MPCNGX . The MPCNGX is a multi-function, sealed, LED ... the right amount of light where and when it’s needed. , A ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 IRIDEX Corporation (NASDAQ: ... offer newly issued shares of common stock, $0.01 par value ... an underwritten public offering.  The final terms of the Offering ... of pricing, and there can be no assurance as to ... IRIDEX expects to use the net proceeds it will receive ...
(Date:12/8/2016)... -- Global Interventional Radiology Market: Scope and Methodology ... market analyzes the current and future prospects of ... summary, including a market snapshot that provides overall ... research is a combination of primary and secondary ... research efforts along with information collected from telephonic ...
(Date:12/8/2016)... 2016  Eli Lilly and Company (NYSE: ... 3 EXPEDITION3 trial at the 9 th Clinical ... solanezumab did not meet the primary endpoint in the ... people with mild dementia due to Alzheimer,s disease (AD), ... for the treatment of mild dementia due to AD. ...
Breaking Medicine Technology: